利伐沙班片治疗什么病症？利伐沙班片的效果怎么样？

Rivaroxaban has the advantages of high bioavailability, extremely convenient use, and rapid absorption after oral administration. The application of rivaroxaban in the treatment of patients can significantly improve cardiac function and pulmonary tissue blood perfusion, resulting in significant improvements in blood gas indicators and echocardiographic indicators. Developed jointly by Bayer Pharma of Germany and Johnson & Johnson of the United States, it is the world's first clinically applied inhibitor that directly acts on coagulation factor Xa.

What conditions does Rivaroxaban tablets treat?

Indications for rivaroxaban include the treatment of venous thromboembolism in adults; for the reduction of stroke in adults with non-valvular atrial fibrillation who have one or more risk factors (e.g., congestive heart failure, hypertension, age ≥75 years, diabetes, history of stroke or transient ischemic attack). Neutralizes the risk of systemic embolism; used to treat venous thrombosis (DVT) in adults and reduce the risk of DVT recurrence and pulmonary embolism (PE) after acute DVT; used in adult patients undergoing elective hip or knee replacement surgery to prevent venous thrombosis (VTE).

How effective is Rivaroxaban tablets?

The clinical data of 80 patients with pulmonary embolism were retrospectively analyzed and divided into two groups according to different treatment plans. Forty patients treated with rivaroxaban were included in the rivaroxaban group, and 40 patients treated with warfarin were included in the warfarin group. The partial pressure of arterial oxygen and the incidence of bleeding events were compared between the two groups.

The results showed that the total effective rates of treatment in the rivaroxaban group and the warfarin group were 92. 50% and 87. 50% respectively, and the difference was not statistically significant. After treatment, the partial pressure of carbon dioxide in arterial blood in both groups was significantly higher than before treatment, and the partial pressure of carbon dioxide in arterial blood was significantly lower than before treatment. The incidence of bleeding events in the rivaroxaban group was lower than that in the warfarin group, and the difference was statistically significant. Conclusion: Rivaroxaban has a significant effect in the treatment of pulmonary embolism, can improve the partial pressure of arterial blood oxygen, has no obvious bleeding events, and is highly safe.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: